

Summary information for preparing PHOSP-COVID Manuscripts December 2022

<p>Authorship</p>	<p>After the manuscript title quote “on behalf of the PHOSP-COVID Study Collaborative Group*”</p> <p>*Provide a complete list of collaborators in the PHOSP-COVID study in the Supplementary Appendix using the two documents below.</p> <p>The full authorship list is available at https://phosp.org/resource for authors to download and all members will be able to self-cite the publication.</p> <ol style="list-style-type: none"> 1. Word - Supplementary Appendix Full Authorship list 2. Excel- Full Authorship list in alphabetical order <p>Writing Group- assume responsibility for the overall content and integrity of the publication. These members will be listed in the main publication. Membership of a Working Group does not alone constitute eligibility for writing group authorship.</p>
<p>Authorship for PHOSP-COVID central manuscripts</p>	<p>The following will consist of the writing group</p> <ul style="list-style-type: none"> • Core Management Group • Core Leicester PHOSP • Key members of data team including Usher Institute, Edinburgh • One working lead for all WGs including imaging and omic platforms • Representation from PHOSP site PIs • Representation from each of the four UK nations <p>When preparing manuscripts, please contact: PHOSPcontracts@leicester.ac.uk for the latest writing group authorship list which contains authors names, email addresses and affiliations</p>
<p>Authorship For PHOSP-COVID Working Group manuscripts</p>	<p>The following will consist of the writing group</p> <ul style="list-style-type: none"> • Specific Working Group members • Core Management Group • Core Leicester PHOSP • Key members of data team including Usher Institute, Edinburgh • Leads for platforms such as imaging and omics where relevant data used <p>When preparing manuscripts, please contact: PHOSPcontracts@leicester.ac.uk for the latest writing group authorship list which contains authors names, email addresses and affiliations</p>
<p>ICJME criteria Reminder</p>	<ol style="list-style-type: none"> 1. Substantial contributions to <ol style="list-style-type: none"> a. the conception or design of the work; b. or the acquisition, c. analysis, or interpretation of data for the work; AND

	<p>2. Drafting the work or revising it critically for important intellectual content; AND</p> <p>3. Final approval of the version to be published; AND</p> <p>4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
Funding	<p>PHOSP-COVID is jointly funded by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19 (grant references: MR/V027859/1 and COV0319). The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.</p>
Ethics	<p>Ethics Approval Ethics Ref: 20/YH/0225</p>
Open Access	<p>This is an Open Access article under the CC BY 4.0 license. The UKRI Open Access Policy can be found: https://www.ukri.org/wp-content/uploads/2022/07/UKRI-28072022-Final_UKRI-Open-Access-Policy_Version-1.5_July-2022.pdf. Authors- must check compliance with UKRI open access policy for each publication.</p>
Contributors	<p>The manuscript was initially drafted by <i>XXX [insert initials]</i>, and further developed by the writing committee. <i>XXX [insert initials]</i> made substantial contributions to the conception and design of the work. <i>XXX [insert initials]</i> made substantial contributions to the acquisition of data. <i>XXX [insert initials]</i> made contributions to the analysis or interpretation of data for the work. <i>XXX [insert initials]</i> verified the underlying data. All authors contributed to data interpretation and critical review and revision of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p>
Affiliations	<p>The affiliations of the members of the writing committee are as follows:....</p>
Declaration of interests	<p>To complete using the Conflict of Interest forms</p>
Data sharing	<p>The protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online</p>
Acknowledgments	<p>This study would not be possible without all the participants who have given their time and support. We thank all the participants and their families. We thank the many research administrators, health-care and social-care professionals who contributed to setting up and delivering the study at all of the 65 NHS trusts/Health boards and 25 research institutions across the UK, as well as all the supporting staff at the NIHR Clinical Research Network, Health Research Authority, Research Ethics Committee, Department of Health and Social Care, Public Health Scotland, and Public Health England,</p>

	<p>and support from the ISARIC Coronavirus Clinical Characterisation Consortium. We thank Kate Holmes at the NIHR Office for Clinical Research Infrastructure (NOCRI) for her support in coordinating the charities group. The PHOSP-COVID industry framework was formed to provide advice and support in commercial discussions, and we thank the Association of the British Pharmaceutical Industry as well NOCRI for coordinating this. We are very grateful to all the charities that have provided insight to the study: Action Pulmonary Fibrosis, Alzheimer’s Research UK, Asthma + Lung UK, British Heart Foundation, Diabetes UK, Cystic Fibrosis Trust, Kidney Research UK, MQ Mental Health, Muscular Dystrophy UK, Stroke Association Blood Cancer UK, McPin Foundations, and Versus Arthritis. We thank the NIHR Leicester Biomedical Research Centre patient and public involvement group and Long Covid Support.</p>
Dissemination	<p>The PPI charities group in PHOSP is leading the dissemination to relevant patient groups.</p>
PPI involvement	<p>Patient and public involvement have been integral to the PHOSP-COVID study and consortium since conception. The PHOSP PPI group is co-chaired by NOCRI (Kate Holmes) and BLF/Asthma UK (Krisnah Poinasamy) with representation of over 10 relevant charities. Members of the ‘Long-COVID Facebook support group’ are closely involved and a Leicester BRC PPI group consisting of people with lived experience of a hospital admission for COVID-19. Patients and public are embedded within the PHOSP infrastructure including our working groups, core management group, and executive and steering groups. Patients were involved in the development of the clinical research study including the overarching aims, choice of outcomes, consent processes and the structure of the study visits. Patients review all patient facing material. We have recently completed a joint patient and clinician research priority questions exercise hosted by advisors from the James Lind Alliance to ensure co-ownership of the direction of PHOSP-COVID research. The data presented in the current manuscript starts to answer the co-identified top ten priorities.</p>
Protocol Changes	<p>The final protocol relevant to this study is available in the supplementary material to this publication including summary of changes (appendix X).</p> <p>Authors- the most recent version is available to download https://phosp.org/resource/ which includes all protocol Changes</p>

For queries contact phospcontracts@le.ac.uk